2 primary sources checked1 reported, unconfirmedReviewed 12 Aug 2026
Exosome treatments — marketed as an advanced “cellular” upgrade to standard skin boosters — have become one of the most heavily promoted add-ons at Korean skin clinics. They also sit in one of the clearest regulatory gaps in the industry: not approved as a drug anywhere that matters, banned from cosmetic advertising in Korea, and the subject of at least one court case over what happens when a doctor injects one anyway.
No FDA-approved exosome product exists
The U.S. Food and Drug Administration has been explicit on this point since a public safety notification issued December 6, 2019: “There are currently no FDA-approved exosome products.” The agency classifies exosomes intended to treat or prevent disease as drugs and biological products, meaning they require premarket review — the same bar as any new medication. That statement has not changed as of 2026; the approval count remains zero. The FDA’s notification followed reports of serious adverse reactions in patients who received unapproved exosome products at U.S. clinics, and it recommends patients ask any provider offering exosome treatment for the product’s investigational drug (IND) application number before proceeding — a number that, for cosmetic use, generally does not exist.
Korea moved to restrict the marketing, not the treatment
South Korea’s drug and cosmetics regulator, the Ministry of Food and Drug Safety (MFDS), revised its cosmetic labeling and advertising guidance on January 21, 2025, expanding the list of banned claims. “Exosome” was added directly — cosmetics can no longer market themselves using the term, alongside other newly banned phrases like “hospital-exclusive,” “dermatology-clinic-use,” and specific numeric anti-aging claims. The restriction targets advertising language for cosmetic products, not the clinical use of exosome injections themselves, which fall under a separate part of the regulatory system entirely.
A Seoul court has already ruled on what happens when the line is crossed
In a decision dated April 11, 2025, the Seoul Administrative Court’s First Division upheld a three-month license suspension for a physician who, in August 2022, injected a topical cosmetic product called ASCE+ — registered only as a cosmetic, not approved as a drug and never reported for injectable use — directly into a patient’s face by hand. The court’s reasoning is worth noting: it held that what matters is not how a product is labeled or where it’s sold, but how it’s actually used and what it physiologically does once injected. The ruling found the unauthorized injection itself was the violation, independent of whether the patient was harmed.
What this means if a clinic offers you an “exosome” treatment
The word itself tells you very little. It doesn’t confirm the product is a genuine biologic exosome preparation, doesn’t confirm it’s approved for injection anywhere, and in Korea, a clinic marketing a cosmetic product by that name is technically violating advertising rules that took effect in 2025. Worth asking directly: what is the product’s actual regulatory classification — cosmetic or drug — and is it approved or reported for injectable use. If a clinic can’t answer clearly, that’s the same signal covered in the MFDS’s advertising crackdown and the court’s ruling: a product’s marketing name and its actual legal status are two different things.
Regulatory statements and case details in this article are drawn from the FDA’s public safety notification, MFDS guidance documents, and Korean court reporting on the April 2025 Seoul Administrative Court ruling.